In a remarkable scientific breakthrough, Nigerian-born, U.S.-based solid-state organic chemist, Charles Izuchukwu Ezekiel has identified a next-generation biologically active molecule with the potential to revolutionize prostate cancer treatment.
His research suggests that this molecule can effectively combat castration-resistant prostate cancer (CRPC)—a particularly aggressive form of the disease that affects approximately 299,010 American men and causes 35,250 deaths annually, according to the World Health Organization (WHO).
In an exclusive interview with The Guardian, Mr. Ezekiel shared that his discovery was inspired by his deep expertise in crystal engineering. His relentless pursuit of knowledge led him to analyze the crystal structure and stereochemistry of a similar patented molecule, ultimately unveiling a more effective compound.
“The preliminary results from biological studies have been nothing short of extraordinary,” he explained. “Our molecule outperforms some existing drugs currently available for prostate cancer treatment.”
This groundbreaking research, conducted in collaboration with leading experts in health and internal medicine, shows that the molecule can inhibit androgen receptor-mediated gene expression, cell proliferation, and tumor growth—offering new hope to prostate cancer patients worldwide.
With over a decade of research experience in pharmaceutics and small-molecule drug synthesis, Ezekiel is determined to push the boundaries of pharmaceutical innovation. Holding an MSc in Chemistry from Rhodes University, South Africa, he is currently completing his PhD at the University of Iowa, USA.
His research focuses on the development of new solid forms of functional organic materials with wide-ranging applications in pharmaceutics, energy storage, electronics, industrial gas separation, and agriculture.
Reflecting on his past achievements, Ezekiel highlighted one of his pioneering contributions to cancer treatment, the development of an echogenic liposome, a smart nanoparticle designed to deliver 5-fluorouracil, an anticancer drug, directly to tumor cells.
This cutting-edge drug delivery system encapsulated argon gas, making it responsive to ultrasound stimuli.
This innovation enabled the targeted release of the drug, significantly reducing toxicity to healthy cells while maximizing efficacy against cancerous ones.
Ezekiel’s research also tackles one of the biggest challenges in drug development— bioavailability.
Currently, about 40% of approved drugs and 90% of drugs in the development pipeline belong to the Biopharmaceutical Classification System (BCS) class II, meaning they have high permeability but low solubility, which affects how well they work in the body.
“More research is needed to enhance drug performance,” he said. “I have already identified several active pharmaceutical ingredients (APIs) and coformers to improve these properties, and I am excited about the potential impact.”
Beyond pharmaceuticals, Ezekiel underscores the immense technological and economic potential of functional materials—crystalline solids whose properties influence everything from drug solubility to electronic devices.
“The way molecules are arranged in a crystal lattice determines their solubility, stability, and effectiveness,” he explained. “By designing new solid forms, we can enhance drug efficacy, support economic growth, improve healthcare, and protect the environment.”
His work contributes to the global competitiveness of the U.S. healthcare and pharmaceutical industries, ensuring continued innovation and economic sustainability.
Ezekiel’s career extends beyond academia.
Having spent over a decade in Nigeria’s oil and gas industry as a laboratory chemist and offshore logistics superintendent at Union Maritime Ltd, he brings a wealth of practical experience to his research.
He is a specialist in crystallography, utilizing sophisticated techniques like powder X-ray diffraction and single-crystal X-ray diffraction to develop groundbreaking materials.
But his vision extends beyond U.S. laboratories. He is deeply committed to helping developing nations like Nigeria tackle critical health issues such as prostate cancer and counterfeit drugs.
“Nigeria faces serious healthcare challenges,” he emphasized. “If the government invests in pharmaceutical research and crystallography, we can develop better treatments and improve public health.”
Despite his international impact, Ezekiel remains focused on making a meaningful contribution to the global scientific community.
“I am passionate about applying my extensive academic and industrial experience to transform pharmaceutical research,” he said. “This work will not only benefit the U.S. healthcare sector but also pave the way for new discoveries that can save lives worldwide.”
With his unwavering determination and pioneering research, Charles Izuchukwu Ezekiel is shaping the future of medicine, bringing new hope to cancer patients and revolutionizing pharmaceutical science in the process.
